-transparent.png){kind=logo}
We examined the auditory function of 29 subjects affected by homozygous beta-thalassemia, managed with an high transfusion scheme and regularly treated with 40-60 mg/kg/day of desferrioxamine. A group of 29 healthy subjects is studied as control. We found conductive hearing defect in 8 thalassemics (6 bilateral) and sensory-neural hearing loss at high frequencies in 4. Thalassemic patients showed more auditory impairment than controls, an higher incidence of tonsillar hypertrophy, adenotonsillitis and submandibular lymph-node enlargement.
Related Publications
M Stura, and
R Arigliani, and
A C Molinari, and
V Tarantino
September 1986,
The Journal of pediatrics,
M Stura, and
R Arigliani, and
A C Molinari, and
V Tarantino
June 1977,
Helvetica paediatrica acta,
M Stura, and
R Arigliani, and
A C Molinari, and
V Tarantino
January 1991,
Klinische Padiatrie,
M Stura, and
R Arigliani, and
A C Molinari, and
V Tarantino
November 2002,
Harefuah,
M Stura, and
R Arigliani, and
A C Molinari, and
V Tarantino
January 1989,
Blood,
M Stura, and
R Arigliani, and
A C Molinari, and
V Tarantino
January 1985,
Haematologica,
M Stura, and
R Arigliani, and
A C Molinari, and
V Tarantino
December 1975,
The Journal of pediatrics,
M Stura, and
R Arigliani, and
A C Molinari, and
V Tarantino
May 2000,
Annals of the New York Academy of Sciences,
M Stura, and
R Arigliani, and
A C Molinari, and
V Tarantino
October 1989,
American journal of ophthalmology,
M Stura, and
R Arigliani, and
A C Molinari, and
V Tarantino
January 1981,
Acta haematologica,
